Organogenesis Holdings Inc. (ORGO) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Organogenesis Holdings Inc. (ORGO) Healthcare & Pipeline Overview

Organogenesis Holdings Inc. develops and commercializes regenerative medicine solutions for advanced wound care and surgical applications. The company's diverse product portfolio, including bioengineered tissues and cellular therapies, addresses unmet needs in hospitals, wound care centers, and physician offices across the United States.

What Is the Investment Thesis for ORGO?

Organogenesis Holdings Inc. presents a notable research candidate within the regenerative medicine space. With a market capitalization of $197M and a P/E ratio of 8.81, the company demonstrates profitability and growth potential. A gross margin of 74.4% indicates strong pricing power and efficient operations. Key growth catalysts include the expansion of the company's product portfolio with pipeline products like PuraPly XT and PuraForce, and increasing adoption of regenerative medicine solutions in wound care and surgical applications. Potential risks include competition from established players and the regulatory approval process for new products.

Based on FMP financials and quantitative analysis

ORGO Key Highlights

Market Cap of $197M indicates a mid-sized player in the regenerative medicine market.

• P/E Ratio of 8.81 suggests the company is potentially undervalued compared to its earnings.
• Profit Margin of 6.6% demonstrates the company's ability to generate profit from its revenue.
• Gross Margin of 74.4% highlights the company's efficient production and pricing strategies.
• Beta of 1.48 indicates higher volatility compared to the market, potentially offering higher returns but also greater risk.

Who Are ORGO's Competitors?

ORGO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are ORGO's Key Strengths?

Diverse product portfolio in wound care and surgical solutions

• Proprietary bioengineered tissue technologies
• Established sales channels and customer relationships
• Strong gross margin indicating pricing power

What Are ORGO's Weaknesses?

Reliance on a limited number of key products

• Exposure to regulatory risks and approval processes
• Competition from established players in the wound care market
• Potential for product liability claims

What Could Drive ORGO Stock Higher?

Potential FDA approval of PuraPly XT and PuraPly MZ for expanded wound care applications.

• Increasing adoption of NuCel in orthopedic and neurosurgical procedures.
• Commercialization of PuraForce surgical matrix for soft tissue reinforcement.
• Expansion into international markets, such as Europe and Asia.

What Are the Key Risks for ORGO?

Financial-distress signal — its Altman Z-Score of 1.75 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-0.1%) — the business is not currently generating profit on shareholder capital.
• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Competition from established players in the wound care market.
• Regulatory changes and approval delays for new products.
• Product liability claims related to regenerative medicine therapies.
• Economic downturn affecting healthcare spending.

What Are the Growth Opportunities for ORGO?

• Expansion of PuraPly Product Line: Organogenesis is developing PuraPly XT and PuraPly MZ to address a broader range of chronic and acute wounds. The chronic wound care market is estimated to reach $10 billion by 2028, driven by the rising incidence of diabetes and obesity. Successful commercialization of these products could significantly increase Organogenesis's market share and revenue within the next 2-3 years.
• Adoption of NuCel in Surgical Applications: NuCel, a dehydrated placental tissue, is used to support native healing in surgical procedures. The surgical and sports medicine market is experiencing growth due to advancements in minimally invasive techniques and increasing demand for regenerative solutions. Increased adoption of NuCel in orthopedic and neurosurgical applications could drive significant revenue growth over the next 3-5 years.
• Commercialization of PuraForce Surgical Matrix: PuraForce, a bioengineered porcine collagen surgical matrix, is designed for soft tissue reinforcement applications. The market for surgical matrices is growing due to the increasing number of complex surgical procedures and the demand for improved patient outcomes. Successful commercialization of PuraForce could generate substantial revenue within the next 3-4 years.
• Geographic Expansion: Organogenesis primarily operates in the United States. Expanding into international markets, such as Europe and Asia, could unlock significant growth opportunities. The global wound care market is projected to reach $22 billion by 2027, with Asia being the fastest-growing region. International expansion could contribute to revenue growth over the next 5 years.
• Strategic Partnerships and Acquisitions: Organogenesis can pursue strategic partnerships and acquisitions to expand its product portfolio, access new technologies, and strengthen its market position. Collaborating with other companies in the regenerative medicine space could accelerate innovation and drive revenue growth. These partnerships could materialize within the next 1-2 years.

What Are ORGO's Competitive Advantages?

• Proprietary bioengineered tissue technologies
• Established relationships with hospitals and wound care centers
• Strong brand recognition in the advanced wound care market
• Extensive product portfolio addressing diverse clinical needs

What Does ORGO Do?

Founded in 1985 and headquartered in Canton, Massachusetts, Organogenesis Holdings Inc. has evolved into a leading regenerative medicine company. The company focuses on developing, manufacturing, and commercializing innovative solutions for the advanced wound care, and surgical and sports medicine markets. Organogenesis's advanced wound care products include Affinity, Apligraf, Dermagraft, NuShield, PuraPly, and Novachor. These products utilize bioengineered tissues and cellular therapies to promote healing in chronic and acute wounds. The company's surgical and sports medicine products include NuCel, ReNu, FiberOS, and OCMP, which are designed to support tissue regeneration and bone repair in surgical applications. Organogenesis serves a diverse customer base, including hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices, through a direct sales force and independent agencies. The company's pipeline includes PuraPly XT, PuraPly MZ, PuraForce, and TransCyte, targeting expanded applications in wound care and surgical reinforcement.

What Products and Services Does ORGO Offer?

• Develops regenerative medicine solutions for wound care.
• Manufactures bioengineered tissues and cellular therapies.
• Commercializes advanced wound care products like Affinity, Apligraf, and Dermagraft.
• Offers surgical and sports medicine products such as NuCel and ReNu.
• Provides solutions for hospitals, wound care centers, and physician offices.
• Focuses on promoting healing and tissue regeneration.

How Does ORGO Make Money?

• Develops and manufactures regenerative medicine products.
• Sells products directly to hospitals, wound care centers, and physician offices.
• Utilizes a direct sales force and independent agencies for distribution.
• Generates revenue through product sales and licensing agreements.

What Industry Does ORGO Operate In?

Organogenesis Holdings Inc. operates in the growing regenerative medicine market, which is driven by the increasing prevalence of chronic wounds, surgical procedures, and sports-related injuries. The market is characterized by intense competition among established players and emerging companies developing innovative therapies. Organogenesis differentiates itself through its diverse product portfolio, proprietary technologies, and established sales channels. The company's focus on bioengineered tissues and cellular therapies positions it to capitalize on the growing demand for advanced wound care and surgical solutions.

Who Are ORGO's Key Customers?

• Wound care centers
• Government facilities
• Ambulatory service centers
• Physician offices

The most recent 12 insider filings for Organogenesis Holdings Inc. break down as 5 sales and 7 purchases. On net that is roughly 233K shares acquired (about $436K) — insiders putting money in tends to read as conviction.

Quarterly Financial Performance: Organogenesis Holdings Inc.

Revenue for Organogenesis Holdings Inc. came in at $43.8M during Q2 FY2026, a 17.5% improvement versus the preceding quarter. The company recorded a net loss of $99.3M, with diluted EPS of $-0.77. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, ORGO averaged $-0.18 in diluted EPS.

ORGO Valuation & Market Position

With a $197M market cap, Organogenesis Holdings Inc. sits in the micro-cap segment of the market. Analyst price targets span from $2.00 to $3.00, with a consensus of $2.50. At the current price of $1.53, that implies approximately 63% upside potential. Relative to its peer group, ORGO's quantitative score of 37/100 is roughly in line with the peer average of 46/100.

Return on equity for Organogenesis Holdings Inc. stands at -0.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -0.1%, showing how much profit it generates from its asset base. Its free cash flow yield is 5.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.53 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -0.1%, the inverse of the P/E and a quick read on earnings relative to price.

Organogenesis Holdings Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 1.75 places it in the distress zone, a signal of elevated financial risk.

Organogenesis Holdings Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 22.4% above estimates on average.

Company Profile

Organogenesis Holdings Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Canton, US. The company is led by CEO Gary S. Gillheeney. ORGO has traded publicly since 2017.

ORGO Financials

ORGO Latest News

ORGO Analyst Consensus

ORGO MoonshotScore

What Investors Ask About Organogenesis Holdings Inc. (ORGO) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources